ABSTRACT

Although tuberculosis is as old as humanity, its medical treatment began in the 1940's with the discovery of streptomycin. This discovery caused great expectation; However, shortly after it was noticed that patients who received it died just as well as those who did not. This gave way to treatment with multiple drugs due to the growth nature of M. Tuberculosis. Multiple treatments have been given since then, with various organizations worldwide participating. Due to the changing nature of the mycobacteria due to ineffective treatments or insufficient doses, the fight against this bacteria has been long, due to the appearance of monoresistance, polyresistance, evolving until today to the so-called extended resistance. All current research is aimed at better diagnostic tests and treatments that shorten its duration. This article reviews the history of medical treatment of tuberculosis.

KEYWORDS

tuberculosis, Mycobacterium tuberculosis, multidrug resistant, treatment.

REFERENCES

1. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ. 1948;2(4582):769-782.

2. Fox W, Sutherland I, Daniels M. A five-year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis; report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council. Q J Med. 1954;23(91):347-366.

3. Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid; a Medical Research Council investigation. BMJ. 1950;2(4688): 1073-1085.

4. Treatment of pulmonary tuberculosis with isoniazid; an interim report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Br Med J. 1952;2(4787):735-746.

5. Crofton J. Chemotherapy of pulmonary tuberculosis. Br Med J. 1959;1(5138):1610-1614. doi: 10.1136/bmj.1.5138.1610.

6. International Union Against Tuberculosis. An international investigation of the efficacy of chemotherapy in previously untreated patients with pulmonary tuberculosis. Bull Int Union Tuberc. 1964;34(2):83-191.

7. Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa-fifth investigation. A co-operative study in East African hospitals, clinics and laboratories with the collaboration of the East African and British Medical Research Councils. Tubercle. 1970;51(2):123-151.

8. Tuberculosis Chemotherapy Centre. A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull World Health Organ. 1959;21(1):51-144.

9. McCune RM Jr, McDermott W, Tompsett R. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med. 1956;104(5):763-802. doi: 10.1084/jem.104.5.763.

10. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet. 1972;1(7760):1079-1085.

11. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study. Tubercle. 1980;61(2):59-69. doi: 10.1016/0041-3879(80)90012-4.

12. Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African/British Medical Research Council Study. Am Rev Respir Dis. 1976;114(3):471-475. doi: 10.1164/arrd.1976.114.3.471.

13. Controlled trial of 2, 4 and 6 months of pyrazinamide in 6-month, 3× weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis. 1991;143(4 Pt 1):700-706. doi: 10.1164/ajrccm/143.4_pt_1.700.

14. Mitchison DA. The action of antituberculosis drugs in short course chemotherapy. Tubercle. 1985;66(3):218-225. doi: 10.1016/0041-3879(85)90040-6.

15. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet. 2004;364(9441):1244-1251. doi: 10.1016/s0140-6736(04)17141-9.

16. Bjarveit K. The tuberculosis situation in Norway. Scand J Respir Dis. 1978;102:28-35.

17. Nakielna EM, Cragg R, Grzybowski S. Lifelong follow up of inactive tuberculosis: its value and limitations. Am Rev Respir Dis. 1975;112:765-772. doi: 10.1164/arrd.1975.112.6.765.

18. Enarson DA. Tuberculosis control in low-income countries. In: Reichman LE, Hershfield ES, editors. Tuberculosis. A comprehensive international approach. 2da ed. New York: Marcel Dekker, 2000.p. 55-71.

19. Farga V, Caminero JA. La conquista de la tuberculosis. En: Farga V, Caminero JA. Tuberculosis. 3ra. Ed. Chile: Mediterráneo, 2011. p.3-13.

20. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10 Suppl 2):S231-S279.

21. Fox W. The current status of short course of chemotherapy. Tubercle. 1979;60:177-190.

22. World Health Organization. Who tuberculosis program; framework for effective control. WHO/TB 1994:179.

23. Pablos-Méndez A, Raviglione MC, Lazlo A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis drug resistance. 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 1998;338(23):1641-1649. doi: 10.1056/nejm199806043382301.

24. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, King SJ, Renero A, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 2001;344(17):1294-1303. doi: 10.1056/nejm200104263441706.

25. Anti-tuberculosis drug resistance in the world: fourth global report. WHO/HTM/TB/2008.394.

26. WHO/International Union against Tuberculosis Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Geneva: WHO, 1997:WHO/TB/97.229.

27. Granich RM, Balandrano S, Santaella JS, Binkin NJ, Castro KG, Márquez- Fiol A, et al. Survey of drug resistance of Mycobacterium tuberculosis in 3 Mexican states, 1997. Arch Intern Med. 2000;160(5):639-644. doi: 10.1001/archinte.160.5.639.

28. Ait-Khaled N, Alarcón E, Armengol R, Bissel K, Boillot F, Caminero JA. Management of tuberculosis: A guide to the essentials of good practice. Paris, France: International Union Against Tuberculosis and Lung Diseases, 2010.

29. World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. WHO/HTM/TB/2009.420. Geneva, Switzerland: WHO, 2010.

30. World Health Organization. Guidelines for treatment of drug susceptible tuberculosis and patient care. WHO/HTM/TB/2017.05. Geneva, Switzerland: WHO, 2017.

31. Cohen DB, Meghji J, Squire SB. A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis. Int J Tuberc Lung Dis. 2018;22(10):1127-1134. doi: 10.5588/ijtld.17.0705.

32. Suárez PG, Floyd K, Portocarrero J, Alarcón E, Rapiti E, Ramos G, et. al. Feasibility and cost-effectiveness of standardized second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet. 2002;359(9322):1980-1989. doi: 10.1016/s0140-6736(02)08830-x.

33. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horseburgh Jr CR. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993;328(8):527-532. doi: 10.1056/nejm199302253280802.

34. Van Deun A, Hamid Salim MA, Kumar Das AP, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis. 2004;8(5):560-567.

35. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010:182(5):684-692. doi: 10.1164/rccm.201001-0077oc.

36. Nunn AJ, Rusen ID, Van Deun A, Torrea G, Phillips PP, Chiang CY, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials. 2014;15:353. doi: 10.1186/1745-6215-15-353.

37. Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet. 2022;400(10366):1858-1868. doi: 10.1016/S0140-6736(22)02078-5.

38. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397-2405. doi: 10.1056/nejmoa0808427.

39. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151-2160. doi: 10.1056/nejmoa1112433.

40. Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother. 2012;56(6):3027-3031. doi: 10.1128/aac.06125-11.

41. Palomino JC, Martin A. Is repositioning of drugs a viable alternative in the treatment of tuberculosis? J Antimicrob Chemother. 2013;68(2):275-283. doi: 10.1093/jac/dks405.

42. Conradie F, Diacon AH, MD, Ngubane N, Howell P, Everitt D, M. Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893-902. doi: 10.1056/nejmoa1901814.

43. Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline–pretomanid–linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022;387(9):810-823. doi: 10.1056/nejmoa2119430.

44. WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.